Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JNJ-73763989 + PD-1 inhibitor + nucleos(t)ide analog
- Development stage
- Unknown
- Lead developer
- Janssen Research & Development
- Modality
- Small Molecules, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous, Oral, Intravenous
01
Overview
This is a **combination therapy** comprised of three elements: - **JNJ-73763989**, a short interfering RNA (siRNA) drug designed to target all messenger RNAs of hepatitis B virus (HBV), thereby reducing the expression of all viral proteins. It is administered subcutaneously and is being developed as a potential functional cure for chronic hepatitis B. - **PD-1 inhibitor**, an immunotherapy (checkpoint inhibitor) that blocks the programmed cell death protein 1 (PD-1) pathway to enhance immune responses against HBV-infected cells. This class includes drugs such as pembrolizumab or nivolumab, both monoclonal antibodies. - **Nucleos(t)ide analog**, a class of oral small molecule antivirals (e.g., entecavir, tenofovir disoproxil, or tenofovir alafenamide) that inhibit reverse transcription in HBV and suppress viral replication. The aim of this combination is to profoundly suppress HBV (and in some studies, hepatitis D virus as well), boost immune clearance of infected cells, and potentially enable a functional cure of chronic hepatitis B.
- Other names
- JNJ-3989 + PD-1 inhibitor + nucleos(t)ide analog
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)HBV Pol (Hepatitis B virus polymerase)HBV RNA (Hepatitis B virus RNA)
Beyond the preview
Go deeper on JNJ-73763989 + PD-1 inhibitor + nucleos(t)ide analog.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JNJ-73763989 + PD-1 inhibitor + nucleos(t)ide analog.